ECG of the Month. Sinus arrhythmia in an African grey parrot.

S. Musulin,D. Adin

DOI: https://doi.org/10.2460/JAVMA.229.4.505

2006-08-15

Journal of the American Veterinary Medical Association

Abstract:

What problem does this paper attempt to address?

Microfluidic Assaying of Circulating Tumor Cells and Its Application in Risk Stratification of Urothelial Bladder Cancer

Guanghou Fu,Kok Suen Cheng,Anqi Chen,Zhijie Xu,Xiaoyi Chen,Junjie Tian,Congcong Xu,Yukun Sun,Kuang Hong Neoh,Yun Dai,Ray P. S. Han,Baiye Jin

DOI: https://doi.org/10.3389/fonc.2021.701298

IF: 4.7

2021-01-01

Frontiers in Oncology

Abstract:Bladder cancer is characterized by its frequent recurrence and progression. Effective treatment strategies need to be based on an accurate risk stratification, in which muscle invasiveness and tumor grade represent the two most important factors. Traditional imaging techniques provide preliminary information about muscle invasiveness but are lacking in terms of accuracy. Although as the gold standard, pathological biopsy is only available after the surgery and cannot be performed longitudinally for long-term surveillance. In this work, we developed a microfluidic approach that interrogates circulating tumor cells (CTCs) in the peripheral blood of bladder cancer patients to reflect the risk stratification of the disease. In a cohort of 48 bladder cancer patients comprising 33 non-muscle invasive bladder cancer (NMIBC) cases and 15 muscle invasive bladder cancer (MIBC) cases, the CTC count was found to be considerably higher in the MIBC group compared with the NMIBC group (4.67 vs. 1.88 CTCs/3 mL, P=0.019), and was significantly higher in high-grade bladder cancer patients verses low-grade bladder cancer patients (3.69 vs. 1.18 CTCs/3mL, P=0.024). This microfluidic assay of CTCs is believed to be a promising complementary tool for the risk stratification of bladder cancer.
Microfluidic Assaying of Circulating Tumor Cells and its Correlation with Muscle Invasiveness and Tumor Grade of Urothelial Bladder Cancer

Guanghou Fu,Kok Suen Cheng,Anqi Chen,Zhijie Xu,Xiaoyi Chen,Junjie Tian,Congcong Xu,Yukun Sun,Kuang Hong Neoh,Yun Dai,Ray P.S. Han,Baiye Jin

DOI: https://doi.org/10.21203/rs.3.rs-267304/v1

2021-01-01

Abstract:Abstract Background: Bladder cancer is characterized by its frequent recurrence and progression. Effective treatment strategies need to be based on an accurate risk stratification, in which muscle invasiveness and tumor grade represent the two most important factors. Traditional imaging techniques provide preliminary information about muscle invasiveness but are lacking in terms of accuracy. Although as the gold standard, pathological biopsy is only available after the surgery and cannot be performed longitudinally for long-term surveillance. Methods: In this work, we developed a microfluidic approach that interrogates circulating tumor cells (CTCs) in the peripheral blood of bladder cancer patients to reflect the risk stratification of the disease. Results：In a cohort of 48 bladder cancer patients comprising 33 non-muscle invasive bladder cancer (NMIBC) cases and 15 muscle invasive bladder cancer (MIBC) cases, the CTC count was found to be considerably higher in the MIBC group compared with the NMIBC group (4.67 vs. 1.88 CTCs/3 mL, P=0.019), and was significantly higher in high-grade bladder cancer patients verses low-grade bladder cancer patients (3.69 vs. 1.18 CTCs/3mL, P=0.024). Conclusions: This microfluidic assay of CTCs is believed to be a promising complementary tool for the risk stratification of bladder cancer.Trial registration: This research was conducted under the approval of the Ethics Committee of the First Affiliated Hospital at Zhejiang University School of Medicine with the Registration No. 2015-218.
Urine cytology suspicious for urothelial carcinoma: Prospective follow-up of cases using cytology and urine biomarker-based ancillary techniques

Ruth Montalbo,Laura Izquierdo,Mercedes Ingelmo-Torres,Pilar Galve,Manel Solé,Agustín Franco,María José Ribal,Antonio Alcaraz,Lourdes Mengual

DOI: https://doi.org/10.1002/cncy.22252

Abstract:Background: Urine cytology results that are suspicious for urothelial carcinoma (UC) are challenging. The objective of this study was to elucidate the clinical significance of such results in patients who have a negative cystoscopy. Methods: In this prospective study, 83 patients who had urine cytology that was suspicious of UC and a negative cystoscopy underwent a second cystoscopy and urine evaluation by cytology, UroVysion fluorescence in situ hybridization (FISH) assay, FGFR3 (fibroblast growth factor receptor 3) and TERT (telomerase reverse transcriptase) mutations and an 8-gene expression classifier (GEC). Results from all techniques were compared with patients' clinical outcomes. Results: The presence of tumor was identified in 41% of patients; of these, 82% had tumors identified at their second evaluation (76% high-grade [HG] tumors), and 18% had tumors identified at a later follow-up (50% were HG tumors). After The Paris System for Reporting urinary Cytology (TPS) reclassification, 53 cytology results still had an indeterminate diagnosis (13 were suspicious for HGUC, and 40 had atypical urothelial cells (AUCs)]. Complete results from second evaluations using urine cytology, cytology-TPS, FISH, and GEC were available for 6 cases that were suspicious for HGUC and 34 cases that had AUCs. The sensitivity of these techniques to detect HG tumors in cases that were suspicious for HGUC was 100%, except for cytology-TPS, for which the sensitivity was 50%. The sensitivity of cytology and cytology-TPS to detect HG tumors in cases with AUCs was 33%, whereas the sensitivity of fluorescence in situ hybridization and GEC in these cases was 83% and 75%, respectively, to detect HG tumors at the second evaluation. Conclusions: The current results indicate the relevant clinical significance of indeterminate urine cytology findings and strongly suggest the use of complementary evaluations by urine biomarker-based, ancillary techniques to elucidate their significance.
Diagnostic Value of Urine Cytology in Pharmacologically Forced Diuresis for Upper Tract Urothelial Carcinoma Diagnosis and Follow-Up

Nicola Giudici,Jennifer Blarer,Niranjan Sathianathen,Fiona C. Burkhard,Patrick Y. Wuethrich,George N. Thalmann,Roland Seiler,Marc A. Furrer

DOI: https://doi.org/10.3390/cancers16040758

2024-02-13

Cancers

Abstract:We performed a urine cytology analysis of a pharmacologically induced diuresis for the diagnosis of upper tract urothelial carcinoma. To evaluate the diagnostic value of cytology of pharmacologically forced diuresis, an initial cohort of 77 consecutive patients with primary upper tract urothelial carcinoma treated via radical surgery was enrolled. To evaluate pharmacologically forced diuresis cytology as a follow-up procedure, a second cohort of 1250 patients who underwent a radical cystectomy for bladder cancer was selected. In the first cohort, the sensitivity of cytology of pharmacologically forced diuresis in patients with invasive, high-grade, low-grade, and concomitant carcinoma in situ was 8%, 9%, 0%, and 14%, respectively. In the second cohort, cytology of pharmacologically forced diuresis was positive in 30/689 (4.3%) patients, in whom upper urinary tract recurrence was present in 21/30 (70%) of cases, and urethral recurrence was present in 8/30 (26%) of cases. As a follow-up tool, cytology of pharmacologically forced diuresis showed a sensitivity, specificity, and positive and negative predictive values of 60%, 99%, 70%, and 98%, respectively. Overall, as a diagnostic tool, the sensitivity of cytology of pharmacologically forced diuresis is slightly better in patients with invasive upper tract urothelial carcinoma and concomitant carcinoma in situ. As a follow-up method, positive cytology of pharmacologically forced diuresis is strongly related to cancer recurrence and can reveal urethral recurrence. Cytology of pharmacologically forced diuresis might be useful in cases with contraindications for imaging or when achieving endoscopic access to the upper urinary tract is difficult.

oncology
Diagnostic value of Xpert® BC Detection, Bladder Epicheck®, Urovysion® FISH and cytology in the detection of upper urinary tract urothelial carcinoma

Stefan Pycha,Emanuela Trenti,Christine Mian,Christine Schwienbacher,Esther Hanspeter,Margherita Palermo,Armin Pycha,Hansjörg Danuser,Carolina D'Elia

DOI: https://doi.org/10.1007/s00345-023-04350-x

Abstract:Purpose: Following the current guidelines, diagnosis and staging for upper urinary tract tumours (UTUC) can be performed with Computed Tomography, urography, ureterorenoscopy (URS) and selective cytology. The aim of the study was to evaluate the performance of the Xpert®-BC-Detection and the Bladder-Epicheck®-test in the detection of UTUC and compare it with cytology and the Urovysion®-FISH test using histology and URS as gold standard. Methods: A total of 97 analyses were collected through selective catheterization of the ureter before URS to test for cytology, Xpert®-BC-Detection, Bladder-Epicheck® and Urovysion®-FISH. Sensitivity, specificity, and predictive values were calculated using histology results/URS as reference. Results: Overall sensitivity was 100% for Xpert®-BC-Detection, 41.9% for cytology, 64.5% for Bladder-Epicheck® and 87.1% for Urovysion®-FISH. The sensitivity of Xpert®-BC-Detection was 100% in both, LG and HG tumours, sensitivity of cytology increased from 30.8% in LG to 100% in HG, for Bladder-Epicheck® from 57.7% in LG to 100% in HG and of Urovysion®-FISH from 84.6% in LG to 100% in HG tumours. Specificity was 4.5% for Xpert®-BC-Detection, 93.9% for cytology, 78.8% for Bladder-Epicheck® and 81.8% for Urovysion®-FISH. PPV was 33% for Xpert®-BC-Detection, 76.5% for cytology, 58.8% for Bladder-Epicheck® and 69.2% for Urovysion®FISH. NPV was 100% for Xpert®-BC-Detection, 77.5% for cytology, 82.5% for Bladder-Epicheck® and 93.1% for Urovysion®FISH. Conclusion: Bladder-Epicheck® and Urovysion®FISH along with cytology could be a helpful ancillary method in the diagnosis and follow-up of UTUC while due to its low specificity Xpert®-BC Detection seems to be of limited usefulness.
The Role of Bladder-Washing Cytology as an Adjunctive Method to Cystoscopy During Follow-Up for Low-Grade TaT1 Non-Muscle-Invasive Bladder Cancer

Enric Carbonell,Clàudia Mercader,Héctor Alfambra,Paulette Narvaez,Eric Villalba,Rita Pagès,Ignacio Asiain,Meritxell Costa,Agustín Franco,Antonio Alcaraz,María José Ribal,Antoni Vilaseca

DOI: https://doi.org/10.3390/cancers16213708

2024-11-02

Cancers

Abstract:Background and Objective: The role of urine cytology during follow-up for low-grade (LG) non-muscle-invasive bladder cancer (NMIBC) is not well established, although cytology has low sensitivity in detecting LG recurrences. Our study aims to evaluate the impact of urine cytology as a complementary method to cystoscopy during follow-up for LG NMIBC. Methods: Patients diagnosed with primary LG TaT1 bladder cancer (BC) between 2010 and 2020 were included. Patients were stratified according to the EAU NMIBC scoring model. Urine cytology was performed during follow-up cystoscopy. The outcomes of the study were BC recurrence and upgrading to high-grade (HG). Cytology utility was established by assessing whether its result led to management change. Results: We included 337 patients with LG TaT1 BC. EAU risk group distribution was low in 262 (77.7%), intermediate in 57 (16.9%), and high-risk in 18 (5.3%) cases. With a median follow-up of 5 years, 166 (49.3%) patients experienced recurrence. Cystoscopy was positive in 154 (92.8%) and suspicious in 12 (7.2%) cases. Urine cytology was positive in 33 (19.9%) cases but only changed management in 3 (0.89%), all with suspicious cystoscopy. Positive cytology at first recurrence was associated with higher risk of upgrading during follow-up (HR 2.781, p = 0.006) and lower upgrading-free survival (p = 0.001). Conclusion: The role of urine cytology to detect first recurrences during follow-up for primary LG TaT1 NMIBC might be limited to patients with non-conclusive lesions in the cystoscopy. A positive cytology at first recurrence is associated with a higher risk of upgrading to HG BC during follow-up.

oncology
Correlation of histopathological, cytological and flow cytometric findings in neoplastic and nonneoplastic lesions of the bladder

D F Cowan,B Wu,G P Young,O P Khanna

DOI: https://doi.org/10.1016/s0022-5347(17)43360-x

Abstract:Biopsy diagnosis, urine cytology and flow cytometry features of urine and bladder washings were compared in 81 cases of benign and malignant bladder disease. Some patients were followed by urine cytology and flow cytometry during treatment of tumors. There was a good correlation of the 3 parameters in relatively high grade tumors (II and III) but an inconsistent appearance of cells in the urine diagnosable by either urine cytology or flow cytometry for low grade lesions. High grade flat neoplasms may be detectable by urine cytology and flow cytometry before they are visible on endoscopy. Flow cytometry may indicate urothelial proliferation before it is apparent on urine cytology. Exfoliative benign lesions are diagnosed readily by the combination of urine cytology and flow cytometry. In benign and malignant lesions shedding of viable cells and, therefore, accessibility to urine cytology and flow cytometry are inconsistent. The need for repeated examinations in the case of low grade lesions suggests that the method is not reliable for single test screening programs but it is a valuable means of followup in cases of suspected or diagnosed disease.
Dependence of mixed disulfide formation in alveolar macrophages upon production of oxidized glutathione: effect of selenium depletion.

George A. Loeb,Dianne C. Skelton,Dianne C. Skelton,Henry Jay Forman,Henry Jay Forman

DOI: https://doi.org/10.1016/0006-2952(89)90024-5

IF: 6.1

1989-09-15

Biochemical Pharmacology

Abstract:
Combined application of cytology and molecular urine markers to improve the detection of urothelial carcinoma

Tilman Todenhöfer,Jörg Hennenlotter,Michael Esser,Sarah Mohrhardt,Veronika Tews,Stefan Aufderklamm,Georgios Gakis,Ursula Kuehs,Arnulf Stenzl,Christian Schwentner

DOI: https://doi.org/10.1002/cncy.21247

Abstract:Background: The sensitivity of cytology for the detection of urothelial carcinoma (UC) is limited. Newer methods such as fluorescence in situ hybridization (FISH), immunocytology (uCyt+), and protein markers have been developed to improve urine-based detection of UC. As only little is known regarding the combined application of these markers, we investigated whether combinations of 4 of the most broadly available tests (cytology, FISH, uCyt+, and nuclear matrix protein 22 [NMP22-ELISA]) may improve their diagnostic performance. Methods: The study was comprised of 808 patients who were suspected of having UC. All patients underwent urethrocystoscopy and upper urinary tract imaging and, in the case of positive findings, transurethral resection/biopsy. FISH, uCyt+, cytology, and NMP22-ELISA were performed in all patients. Results: UC was diagnosed in 115 patients (14.2%). Cytology and FISH were found to be the single tests with the best overall performance (area under the curve [AUC], 0.78/0.79). Combinations of 2, 3, and 4 markers were found to increase the AUC to various extents compared with the use of single markers. Combining cytology and FISH improved the sensitivity and performance (AUC, 0.83) compared with the single tests and identified 12 tumors that were not detected by cytology alone. The percentage of WHO grade 3/carcinoma in situ tumors not detected by cytology was reduced by 62.5% when FISH was performed in cytology-negative patients. The addition of uCyt+ as a third test further improved performance (AUC, 0.86), whereas the addition of NMP22-ELISA was not found to have any additional influence on the performance of the test combination. Conclusions: The results of the current study support the combined use of urine markers and may form the basis of further studies investigating whether risk stratification based on urine marker combinations may individualize diagnostic algorithms and the surveillance of patients suspected of having UC.
The autonomously replicating parvoviruses of vertebrates.

S. Cotmore,P. Tattersall

DOI: https://doi.org/10.1016/S0065-3527(08)60317-6

Advances in Virus Research

Abstract:
Urine cytology in the detection of renal cell carcinomas – a territory‐wide multi‐institutional retrospective review of more than 2 decades

Joshua J. X. Li,Joanna K. M. Ng,Cheuk‐Yin Tang,Bryan C. H. Chan,Sau Yee Chan,Jasmine H. N. Law,Jeremy Y. Teoh,Christopher J. VandenBussche,Gary M. Tse

DOI: https://doi.org/10.1002/cncy.22789

2024-02-10

Cancer Cytopathology

Abstract:Introduction Compared with urothelial lesions of the upper urinary tract, the diagnostic performance of urine cytology in detection of renal cell carcinomas is underreported. This study aims to establish the role of urine cytology in the assessment of renal carcinomas by a multi‐institute review of urine cytology from nephrectomy confirmed renal cell carcinomas, referenced against renal urothelial and squamous cell carcinomas. Methods Records of nephrectomy performed from the 1990s to 2020s at three hospitals were retrieved and matched to urine cytology specimens collected within 1 year prior. Patient demographics, specimen descriptors, and histology and staging parameters were reviewed and compared against cytologic diagnoses. Results There were 1147 cases of urine cytology matched with renal cell carcinomas, with 666 renal urothelial/squamous carcinomas for comparison. The detection rate for urothelial/squamous (atypia or above [C3+]: 63.1%; suspicious or above [C4+]: 24.0%) were higher than renal cell carcinoma (C3+: 13.1%; C4+: 1.5%) (p

oncology,pathology
Comparison of urinary cytology and fluorescence in situ hybridization in the detection of urothelial neoplasia: An analysis of discordant results

Teresa McHale,N Paul Ohori,Kathy M Cieply,Carol Sherer,Sheldon I Bastacky

DOI: https://doi.org/10.1002/dc.24108

Abstract:Background: We examine the performance of cytology and FISH in the detection of urothelial carcinoma (UC), and explore the reasons for discrepant results, and potential clinical implications. Methods: Urine samples from 89 patients were prospectively collected for simultaneous cytology and UroVysion FISH, and results correlated with concurrent biopsies and/or clinical or histologic follow-up data. Corresponding tissue biopsies, where available, were also evaluated by FISH. Results: Sensitivity and specificity of cytology and FISH for the detection of UC was 54.8% and 92% and 50% and 88%, respectively. Only one of seven false-positive urinary FISH results proved to be an "anticipatory positive" on extended follow-up. Five of eight (62.5%) high grade (HG) carcinomas with false-negative urinary FISH, were negative due to the absence/paucity of FISH-detectable changes in the tumor cells. In atypical cytology cases, the FISH result did not assist in identifying UC. There was no significant difference between an atypical cytology result and a positive FISH result, with respect to the identification of patients with UC. Conclusions: We found urinary cytology to be more sensitivity and specific than FISH in the detection of UC, though the difference was not statistically significant. Up to 24% of HG UCs are FISH negative due to an absence of FISH-detectable abnormalities in the tumor cells. Paucity of neoplastic cells in the urine also contributes to false-negative FISH results in both HG and low grade tumors. Negative urinary FISH cannot be taken alone as indicating the absence of significant disease in patients with atypical cytology.
Utility of Urovysion FISH in Improving the Diagnostic Performance of Urine Cytology

K.C. Sharan Chandrasekaran,Radhika Srinivasan,Radha Uppal,Manish Rohilla,Pranab Dey,Nandita Kakkar,Ravimohan S. Mavuduru

DOI: https://doi.org/10.1159/000540070

2024-07-24

Acta Cytologica

Abstract:Introduction: The atypical urothelial cell (AUC) category in The Paris System (TPS) in urine cytology (UrCy) is a challenging area. This study aims to evaluate the UroVysion fluorescence in-situ hybridization assay(U-FISH) in predicting the outcome of AUC. Additionally, we explored the association of abnormal U-FISH results in high-grade urothelial carcinoma (HGUC) concerning muscularis propria invasion(MPI). Methods: This is a retrospective study, and U-FISH was done on archived Papanicolaou-stained smears. Four cohorts were included: AUC-NN (Non-Neoplastic), AUC-N (Neoplastic), HGUC-MI (muscle-invasive), and HGUC-MF (muscle-free) outcome on histopathology (HPE) and with clinical follow-up of 12 to 29 months. U-FISH was evaluated for diagnostic purposes, and MPI and tumor stage prediction by U-FISH score (UFS; high vs. low) based on copy number gain of chromosomes (Chr). Results: U-FISH was performed on 70 cases (20-AUC-NN, 20-AUC-N, 15-HGUC-MI, and 15-HGUC-MF) and was successful in 58/70 (82.85%) cases. All UC cases showed amplification of ≥2Chr, and all the AUC-NN cases reported non-neoplastic on HPE were negative for U-FISH. U-FISH picked up all carcinoma cases in the AUC-N cohort. Chr3 amplification was statistically significant in differentiating HGUC-MI from HGUC-MF and LGUC cases. Chr3 signals with a cut-off of 6 signals could identify MPI with a sensitivity of 80.95% and specificity of 41.94%. The UFS of the HGUC-MI group was significantly higher than HGUC-MF. Conclusions: U-FISH successfully identified all cases of AUC with neoplastic outcomes. In the HGUC group, there was a difference in cases with and without MPI, which requires further confirmation in a larger prospective cohort.

pathology
The Clinical Application of Fluorescence in Situ Hybridization in Diagnosing Urothelial Carcinoma

Haijiang Zhou,Yong Yan,Liming Song

DOI: https://doi.org/10.7754/Clin.Lab.2016.160323

2016-10-01

Abstract:Background: Chromosomal aberrations in exfoliated urothelial cells have been associated with the development of urothelial carcinoma. This study aimed to evaluate the efficacy of two kinds of fluorescence in situ hybridization (FISH) kit probes in diagnosing urothelial carcinoma (UC). Methods: From February 2009 through September 2014, urine specimens from 89 consecutive patients with urothelial carcinoma and 11 controls with benign disease were collected and analyzed by means of GP FISH and cytology. Urine samples from 50 consecutive patients with urothelial carcinoma and 68 patients with non-urothelial carcinoma with hematuria were also collected and analyzed by UroVysion FISH and cytology. The sensitivity and specificity of two kinds of FISH and cytology in different stages and grades of urothelial carcinoma were statistically analyzed via SPSS 17.0 and compared. Results: The overall sensitivity of GP FISH and cytology were 88.8% (79/89) and 55.1% (49/89), respectively (p < 0.001), and the overall specificity was 90.9% (10/11) and 100.0% (11/11), respectively (p > 0.05). The overall sensitivity of UroVysion FISH and cytology was 68.0% and 18.0%, respectively (p < 0.05), and the overall specificity was 91.2% and 98.5%, respectively (p > 0.05). The sensitivity of FISH and cytology in diagnosing UUT-UC were 88.9% (16/18) and 44.4%(8/18),respectively. The sensitivity of GP FISH and UroVysion FISH in diagnosing UUT-UC were 100% (10/10) and 75.0% (6/8) respectively. Conclusions: FISH is a non-invasive technique with higher sensitivity and similar specificity compared with urine exfoliated cell cytology in diagnosing urothelial carcinoma by detecting the aberrations of chromosome 3, 7, 17, and 9p21. FISH is significantly superior to cytology in diagnosing low stage and low grade urothelial carcinomas. FISH is a very valuable and promising technique in diagnosing urothelial carcinomas.
Parallel Implementing OpenGL on PVM

Wei Li,Xiaohu Huang,N. Zheng

DOI: https://doi.org/10.1016/S0167-8191(97)00090-2

IF: 0.983

1997-12-01

Parallel Computing

Abstract:
Performance of urinary markers in patients with suspicious cystoscopy during follow-up of recurrent non-muscle invasive bladder cancer: BTA stat®, NMP22® BladderChek®, UBC® Rapid Test, CancerCheck® UBC® rapid VISUAL, and uromonitor® in comparison to cytology

Thorsten H. Ecke,Christina J. Meisl,Thorsten Schlomm,Anja Rabien,Flora Labonté,Dezhi Rong,Sebastian Hofbauer,Frank Friedersdorff,Lilli Sommerfeldt,Nella Gagel,Andreas Gössl,Dimitri Barski,Thomas Otto,Camilla M. Grunewald,Günter Niegisch,Martin J.P. Hennig,Mario W. Kramer,Stefan Koch,Jenny Roggisch,Sarah Weiß,Michael Waldner,Johannes Graff,Elke Veltrup,Friederike Linden,Roland Hake,Sebastian Eidt,Ralph M. Wirtz,Tobias Klatte

DOI: https://doi.org/10.1016/j.urology.2024.11.056

IF: 2.633

2024-12-04

Urology

Abstract:Objectives To compare all available rapid tests on a large cohort of recurrent bladder cancer during follow-up in this multicentre-study is the first study. BTA stat®, NMP22® BladderChek®, UBC® Rapid Test CancerCheck® UBC® rapid VISUAL, and uromonitor® are urinary based rapid tests for bladder cancer detection. Methods In total 187 urine samples were analysed from patients with suspected recurrent non-muscle invasive urothelial bladder cancer on cystoscopy during follow-up in a real-world assessment. All suspicious lesions were resected with 110 samples showing recurrent urothelial cancer. Urine samples were analysed by the BTA stat®, NMP22® BladderChek®, UBC® Rapid Test, CancerCheck® UBC® rapid VISUAL, uromonitor®, and cytology. Sensitivities and specificities were calculated by contingency analyses. Results All investigated urinary markers could detect a higher percentage of pathological results in urine of bladder cancer patients compared to urine of tumor free patients. The calculated diagnostic sensitivities for BTA stat®, NMP22® BladderChek®, UBC® Rapid Test, CancerCheck® UBC® rapid VISUAL, uromonitor®, and cytology were 60.0%, 10.0%, 58.0%, 32.0%, 54.5%, and 41.5% for non-muscle invasive low-grade, and 64.0%, 40.0%, 77.8%, 50.0%, 56.0%, and 65.5% for non-muscle invasive high-grade bladder cancer. The specificity was 51.3%, 94.8%, 66.2%, 89.5%, 94.9%, and 66.2%, respectively. Conclusions During follow-up sensitivities and specificities of most urinary markers are higher compared to cytology for the detection of recurrent bladder cancer. BTA stat®, UBC® Rapid Test, and uromonitor® appear useful in this setting.

urology & nephrology
ERAOF: A new RPL protocol objective function for Internet of Things applications

Natanael Sousa,José V. V. Sobral,J. Rodrigues,R. Rabêlo,P. Šolić

2017-07-12

Abstract:Since its definition, RPL (the IPv6 Routing Protocol for Low-Power and Lossy Networks) has been emerging as the standard protocol for routing in Internet of Things (IoT) solutions. RPL is a proactive routing protocol that performs the process of route creation based on Objective Functions (OFs). The OFs are responsible for defining rules and constraints to select the best paths considering different routing metrics. In its definition, RPL does not impose the use of a default OF and indicates that an OF should be selected according to the application. Thus, this paper proposes an Energy Efficient and Path Reliability Aware Objective Function (ERAOF) for IoT applications that requires energy efficiency and reliability in data transmission. The ERAOF is based on the composition of energy and link quality routing metrics. Results show that ERAOF is able to improve the network performance when compared to other OFs available in the literature.
The combined application of urinary liquid-based cytology with fluorescence in situ hybridization and p16/Ki-67 dual immunostaining is valuable for improving the early diagnosis of upper tract urothelial carcinomas

Xueqi Sun,Xubin Liu,Meng Xia,Shicong Yang,Lingyan Fei,Mengqi Zhang,Hanyu Ma,Liantang Wang,Shangwu Chen,Li Yu

DOI: https://doi.org/10.1002/dc.23796

Abstract:Objectives: To evaluate the diagnostic values of urine liquid-based cytology (LBC), fluorescence in situ hybridization (FISH), and p16/Ki-67 dual immunostaining in the detection of upper tract urothelial carcinomas (UTUCs). Methods: Sixty-one patients with UTUCs were retrospectively analyzed. All patients were diagnosed both by urine cytology and by FISH, and histologically confirmed as UTUCs. Thirty-two patients had been stained with p16/Ki-67 dual labeling. Results: The sensitivities for low-grade UTUCs (LGUTUCs) and high-grade UTUCs (HGUTUCs) were 33.3% and 67.4% by LBC, 60% and 69.6% by FISH, and 12.5% and 66.7% by p16/Ki-67 dual labeling, respectively. Conclusions: Our results indicated that LBC was more suitable to identify HGUTUCs, FISH was highly valuable for predicting LGUTUCs, and p16/Ki-67 dual labeling was useful for distinguishing HGUTUCs from LGUTUCs. The combined application of these methods may improve the sensitivity or accuracy in the detection or diagnosis of UTUCs.
Does aortocoronary saphenous vein bypass surgery change the native coronary arteries? An angiographic follow-up of 60 patients.

S. Nitter‐Hauge,K. Levorstad

DOI: https://doi.org/10.1111/J.0954-6820.1980.TB09703.X

2009-04-24

Acta Medica Scandinavica

Abstract:. Progression of disease in the native coronary circulation was studied in 60 patients before and after aortocoronary saphenous vein bypass surgery. The mean interval between the first angiographic study and operation was 2.0 months and the mean interval from operation to second catheterization was 15.3 months. The results from a second arteriographic study after an interval of 12.3 months on 25 comparable patients, with no surgery in between, served as a control material for frequency and severity of the “natural” progression of the disease. Only vessels which were not occluded at the first examination were included in the re-study. In the 60 operated patients, 106 arteries were grafted and 74 ungrafted. Total graft patency at the time of re-study was 66%. Progression was found in segments proximal to the anastomosis in 42% of arteries with patent graft, and in 47% of arteries with occluded graft, whereas in segments distal to the site of anastomosis progression was found in 5% of the arteries with patent graft and in 55% of arteries with occluded graft. Progression of the disease was found in 11% of ungrafted arteries. In the control group, progression of the disease was found in 24%. The study thus shows that after aortocoronary bypass surgery, progression in segments proximal to the anastomosis is significantly higher than in nongrafted arteries. The progression was independent of patency or occlusion of the graf to the vessel. Progression in the segments distal to the anastomosis was not significantly different from the frequency of progression seen in nongrafted arteries if the graft was patent, but was much higher if the graft was occluded.
Upper Tract Urinary Cytology to Detect Upper Tract Urothelial Carcinoma: Using the Johns Hopkins Hospital Template and Evaluation of Its Feasibility.

Longwen Chen,Huiying He,Matthew A. Zarka,Ming Zhou,Cristina Magi-Galluzzi

DOI: https://doi.org/10.4103/1742-6413.161608

2015-01-01

Abstract:INTRODUCTION:Primary upper urinary tract (UT) urothelial carcinoma (UC) is rare. UT washing cytology is often used during UT surveillance. The Johns Hopkins Hospital template (JHHT) is primarily designed to use on lower tract urine cytology and the data on applying JHHT on UT cytology is limited. We herein study the value of UT cytology in detecting UTUC using JHHT in a cohort.MATERIALS AND METHODS:One hundred UT cytologic specimens were retrieved from our database during a 10-year period (2001-2011). For each patient, the cytology specimen with the highest degree of abnormality was selected. Histologic sections of these cases were also studied.RESULTS:Seventy-six cases of UT cytology had histologic follow-up by either serial (>2) endoscopic biopsies or nephroureterectomy or ureterectomy. Among them, the cytologic diagnosis of positive or suspicious for high-grade UC (HGUC) was made in 15 cases; suspicious for low-grade UC (LGUC) in 3 cases; atypical urothelial cells (AUCs) of undetermined significance in 19 cases; and negative in 39 cases. Of the 15 cases with diagnosis of positive for HGUC or AUC-HGUC (AUC-H), 10 had histologically confirmed HGUC, 1 had LGUC, and 4 had benign histology. All 3 cases of cytologically suspicious for LGUC had LGUC on concomitant histology. Among the 19 washings with AUCs with unknown significance, 7 were LGUC, 1 was HGUC, and 11 were benign on histology. Six of 39 cases with negative cytology had UC (3 low-grade and 3 high-grade) on histology. Combining positive and AUC-H for UC diagnoses, sensitivity, and specificity for detecting HGUC were 71.4% and 91.9%, while for LGUC were 21.4% and 100%, respectively.CONCLUSIONS:UT washing cytology has high specificity for detecting UC, especially HGUC. Using JHHT on UT washing cytology is feasible, but the category of LGUC may need modification.

ECG of the Month. Sinus arrhythmia in an African grey parrot.

Microfluidic Assaying of Circulating Tumor Cells and Its Application in Risk Stratification of Urothelial Bladder Cancer

Microfluidic Assaying of Circulating Tumor Cells and its Correlation with Muscle Invasiveness and Tumor Grade of Urothelial Bladder Cancer

Urine cytology suspicious for urothelial carcinoma: Prospective follow-up of cases using cytology and urine biomarker-based ancillary techniques

Diagnostic Value of Urine Cytology in Pharmacologically Forced Diuresis for Upper Tract Urothelial Carcinoma Diagnosis and Follow-Up

Diagnostic value of Xpert® BC Detection, Bladder Epicheck®, Urovysion® FISH and cytology in the detection of upper urinary tract urothelial carcinoma

The Role of Bladder-Washing Cytology as an Adjunctive Method to Cystoscopy During Follow-Up for Low-Grade TaT1 Non-Muscle-Invasive Bladder Cancer

Correlation of histopathological, cytological and flow cytometric findings in neoplastic and nonneoplastic lesions of the bladder

Dependence of mixed disulfide formation in alveolar macrophages upon production of oxidized glutathione: effect of selenium depletion.

Combined application of cytology and molecular urine markers to improve the detection of urothelial carcinoma

The autonomously replicating parvoviruses of vertebrates.

Urine cytology in the detection of renal cell carcinomas – a territory‐wide multi‐institutional retrospective review of more than 2 decades

Comparison of urinary cytology and fluorescence in situ hybridization in the detection of urothelial neoplasia: An analysis of discordant results

Utility of Urovysion FISH in Improving the Diagnostic Performance of Urine Cytology

The Clinical Application of Fluorescence in Situ Hybridization in Diagnosing Urothelial Carcinoma

Parallel Implementing OpenGL on PVM

Performance of urinary markers in patients with suspicious cystoscopy during follow-up of recurrent non-muscle invasive bladder cancer: BTA stat®, NMP22® BladderChek®, UBC® Rapid Test, CancerCheck® UBC® rapid VISUAL, and uromonitor® in comparison to cytology

ERAOF: A new RPL protocol objective function for Internet of Things applications

The combined application of urinary liquid-based cytology with fluorescence in situ hybridization and p16/Ki-67 dual immunostaining is valuable for improving the early diagnosis of upper tract urothelial carcinomas

Does aortocoronary saphenous vein bypass surgery change the native coronary arteries? An angiographic follow-up of 60 patients.

Upper Tract Urinary Cytology to Detect Upper Tract Urothelial Carcinoma: Using the Johns Hopkins Hospital Template and Evaluation of Its Feasibility.